Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) PS Ratio: 2.29

Is Charles River Laboratories International, Inc.’s P/S ratio high or low?

Charles River Laboratories International, Inc.'s P/S ratio of 2.29 is 26% below its 5-year average of 3.08, near the low end of its 5-year range (1.26–7.19).

The P/S ratio for Charles River Laboratories International, Inc. (CRL) is 2.29 as of Wednesday, June 10, 2026. It is above its 12-month average by 7.43% (2.13).

CRL PS Ratio Chart

CRL PS Ratio
2.29+19.90% 1Y
Zoom

CRL Average PS Ratio Chart

CRL Current vs Average PS Ratio Chart

CRL PS Ratio Metrics

PS RATIO

2.29

PS RATIO AVG TTM

2.13

PS RATIO AVG 3Y

2.36

PS RATIO AVG 5Y

3.08

PS RATIO AVG 10Y

3.10

PS RATIO AVG 15Y

2.76

PS RATIO AVG 20Y

2.68

CURRENT VS TTM AVG

+7.43%

CURRENT VS 3Y AVG

-3.07%

CURRENT VS 5Y AVG

-25.56%

CURRENT VS 10Y AVG

-26.12%

CURRENT VS 15Y AVG

-17.15%

CURRENT VS 20Y AVG

-14.41%

CRL Competitors' PS Ratio

NAMEMARKET CAPPS RATIOTTM3Y5Y
Charles River Laboratories International, Inc. (CRL)$9.06B2.292.132.363.08
Bio-Rad Laboratories, Inc. (BIO)$7.89B3.043.033.314.32
Baxter International Inc. (BAX)$10.49B0.921.001.311.80
Hims & Hers Health, Inc. (HIMS)$6.42B2.774.544.204.38
Align Technology, Inc. (ALGN)$12.56B3.072.944.296.15
Hologic, Inc. (HOLX)$16.97B4.163.834.273.99
Moderna, Inc. (MRNA)$18.40B8.256.105.207.12
BioNTech SE (BNTX)$21.81B6.647.566.755.47
Mettler-Toledo International Inc. (MTD)$22.85B5.616.806.987.67
Waters Corporation (WAT)$23.83B7.976.606.586.83

P/S vs. its own history

At 2.29, P/S is cheaper than usual — richer than 35% of its 20-year range.

20-year low

1.09

median

2.58

20-year high

7.19

cheaperricher

Sales Valuation

P/S Ratio

2.29

Market Cap / Annual Revenue

Charles River Laboratories International, Inc. PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Charles River Laboratories International, Inc. PS Ratio FAQ

What is the P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The P/S ratio for CRL stock is 2.29.
Is Charles River Laboratories International, Inc.'s P/S ratio high or low?
Charles River Laboratories International, Inc.'s P/S ratio of 2.29 is 26% below its 5-year average of 3.08, near the low end of its 5-year range (1.26–7.19).
What is the TTM average P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The TTM average P/S ratio for CRL stock is 2.13.
What is the 3Y average P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The 3Y average P/S ratio for CRL stock is 2.36.
What is the 5Y average P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The 5Y average P/S ratio for CRL stock is 3.08.
What is the 10Y average P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The 10Y average P/S ratio for CRL stock is 3.10.
What is the 15Y average P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The 15Y average P/S ratio for CRL stock is 2.76.
What is the 20Y average P/S ratio for Charles River Laboratories International, Inc. (CRL)?
The 20Y average P/S ratio for CRL stock is 2.68.

Charles River Laboratories International, Inc. PS Ratio History

DATEPS RATIO
2026-06-102.29
2026-06-092.31
2026-06-082.27
2026-06-052.20
2026-06-042.26
2026-06-032.19
2026-06-022.12
2026-06-012.21
2026-05-292.20
2026-05-282.20
2026-05-272.00
2026-05-261.91
2026-05-221.95
2026-05-211.93
2026-05-201.90
2026-05-191.85
2026-05-181.82
2026-05-151.83
2026-05-141.93
2026-05-131.98
2026-05-122.05
2026-05-112.05
2026-05-082.16
2026-05-072.21
2026-05-062.23
2026-05-052.27
2026-05-042.11
2026-05-012.03
2026-04-302.05
2026-04-292.01
2026-04-282.04
2026-04-272.10
2026-04-242.08
2026-04-232.06
2026-04-222.27
2026-04-212.24
2026-04-202.27
2026-04-172.25
2026-04-162.17
2026-04-152.21
2026-04-142.20
2026-04-132.19
2026-04-102.15
2026-04-092.15
2026-04-082.15
2026-04-072.08
2026-04-062.06
2026-04-022.13
2026-04-012.14
2026-03-312.11
2026-03-301.96
2026-03-271.95
2026-03-262.02
2026-03-252.03
2026-03-241.95
2026-03-231.94
2026-03-201.88
2026-03-191.88
2026-03-181.93
2026-03-171.88
2026-03-161.86
2026-03-131.91
2026-03-121.87
2026-03-112.07
2026-03-102.05
2026-03-092.17
2026-03-062.14
2026-03-052.22
2026-03-042.20
2026-03-032.15
2026-03-022.19
2026-02-272.19
2026-02-262.15
2026-02-252.05
2026-02-242.04
2026-02-232.00
2026-02-202.07
2026-02-192.01
2026-02-181.94
2026-02-171.95
2026-02-131.98
2026-02-121.95
2026-02-112.04
2026-02-102.23
2026-02-092.28
2026-02-062.32
2026-02-052.26
2026-02-042.48
2026-02-032.47
2026-02-022.62
2026-01-302.59
2026-01-292.60
2026-01-282.66
2026-01-272.70
2026-01-262.73
2026-01-232.70
2026-01-222.75
2026-01-212.79
2026-01-202.68
2026-01-162.70
2026-01-152.75
2026-01-142.66
2026-01-132.69
2026-01-122.69
2026-01-092.71
2026-01-082.65
2026-01-072.66
2026-01-062.65
2026-01-052.56
2026-01-022.49
2025-12-312.45
2025-12-302.48
2025-12-292.50
2025-12-262.50
2025-12-242.50
2025-12-232.49
2025-12-222.49
2025-12-192.42
2025-12-182.38
2025-12-172.41
2025-12-162.40
2025-12-152.43
2025-12-122.37
2025-12-112.39
2025-12-102.39
2025-12-092.28
2025-12-082.30
2025-12-052.26
2025-12-042.26
2025-12-032.27
2025-12-022.15
2025-12-012.16
2025-11-282.19
2025-11-262.20
2025-11-252.19
2025-11-242.09
2025-11-212.06
2025-11-201.99
2025-11-191.99
2025-11-182.00
2025-11-172.00
2025-11-142.06
2025-11-132.08
2025-11-122.11
2025-11-112.13
2025-11-102.08
2025-11-072.06
2025-11-062.10
2025-11-052.06
2025-11-042.18
2025-11-032.19
2025-10-312.20
2025-10-302.19
2025-10-292.21
2025-10-282.30
2025-10-272.39
2025-10-242.41
2025-10-232.34
2025-10-222.29
2025-10-212.30
2025-10-202.25
2025-10-172.19
2025-10-162.14
2025-10-152.09
2025-10-142.08
2025-10-132.09
2025-10-102.04
2025-10-092.11
2025-10-082.12
2025-10-072.08
2025-10-062.14
2025-10-032.17
2025-10-022.15
2025-10-012.09
2025-09-301.92
2025-09-291.80
2025-09-261.82
2025-09-251.78
2025-09-241.83
2025-09-231.84
2025-09-221.88
2025-09-191.90
2025-09-181.92
2025-09-171.87
2025-09-161.86
2025-09-151.86
2025-09-121.87
2025-09-111.96
2025-09-101.88
2025-09-091.93
2025-09-081.98
2025-09-052.01
2025-09-041.99
2025-09-031.99
2025-09-021.97
2025-08-292.00
2025-08-282.00
2025-08-271.99
2025-08-262.00
2025-08-252.01
2025-08-221.98
2025-08-211.89
2025-08-201.95
2025-08-191.94
2025-08-181.92
2025-08-151.92
2025-08-141.91
2025-08-131.90
2025-08-121.87
2025-08-111.82
2025-08-081.82
2025-08-071.83
2025-08-061.84
2025-08-052.12
2025-08-042.12
2025-08-012.11
2025-07-312.14
2025-07-302.23
2025-07-292.26
2025-07-282.26
2025-07-252.24
2025-07-242.24
2025-07-232.12
2025-07-222.07
2025-07-211.89
2025-07-181.95
2025-07-171.98
2025-07-161.96
2025-07-151.95
2025-07-142.00
2025-07-112.02
2025-07-102.07
2025-07-092.01
2025-07-082.00
2025-07-071.95
2025-07-031.99
2025-07-021.99
2025-07-011.95
2025-06-301.92
2025-06-271.90
2025-06-261.92
2025-06-251.90
2025-06-241.88
2025-06-231.86
2025-06-201.86
2025-06-181.84
2025-06-171.83
2025-06-161.91
2025-06-131.89
2025-06-121.92
2025-06-111.91
2025-06-101.91
2025-06-091.86
2025-06-061.83
2025-06-051.79
2025-06-041.81
2025-06-031.75
2025-06-021.71
2025-05-301.71
2025-05-291.74

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster